Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
September 16, 2014, 12:01:49 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 638946
  • Total Topics: 48507
  • Online Today: 194
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Theraclone Sciences of Seattle has made a deal with Gilead Sciences of Californi  (Read 744 times)

0 Members and 1 Guest are viewing this topic.

Offline dico

  • Member
  • Posts: 85
Theraclone Sciences of Seattle has made a deal with Gilead Sciences of California.

http://www.bizjournals.com/sanfrancisco/blog/biotech/2014/07/theraclone-sciences-gilead-gild-hiv-aids.html

Ben Miller
Contributing Editor-
Puget Sound Business Journal

Theraclone Sciences Inc. of Seattle said it's made a deal with Gilead Sciences Inc. that will allow the Foster City-based biotech giant to develop and commercialize Theraclone's neutralizing HIV-antibodies for therapeutic applications in HIV.
The two companies didn't disclose the specific financial details but said Theraclone received an upfront payment. Theraclone also is eligible to receive additional development and commercialization milestone payments.
Gilead (NASDAQ: GILD), led by Chairman and CEO John Martin, is the world's leading developer of treatments for the AIDS virus.
“Through our innovative I-STAR technology, we are able to uncover unique antibodies that have the capacity to neutralize viruses, such as HIV, that are known to mutate and evade current therapies,” said Clifford Stocks, CEO of Theraclone, in a statement.
In December, a planned merger between privately held Theraclone, whose investors include Canaan Partners, Versant Ventures and Amgen Inc. (NASDAQ: AMGN), and PharmAthene Inc. of Maryland was called off.

Offline dico

  • Member
  • Posts: 85
What do you think ?

Offline Matts

  • Member
  • Posts: 214
Normally all the research leads to nothing, but if Gilead pays $$ it has to be something interesting.
Theraclone found 17 broadly neutralizing antibodies in 2011.
Maybe they are so promising that Gilead wants develop a vaccine in the next decade. Money shouldnt be a problem after the Sovaldi success :)

http://www.news-medical.net/news/20110818/Researchers-isolate-17-novel-antibodies-against-HIV.aspx
 
tivicay/kivexa

Offline tryingtostay

  • Member
  • Posts: 197
A vaccine for people who don't have it (HIV) ? or am I reading this wrong?
Labs:
March 2014: CD4 1730 @ 41%, VL 87 without meds
May 2014: CD4 1309 @ 42%, VL <20 without meds
Sept 2014: CD4 1655 @ 42%, VL xxxx  - waiting for results

Offline Cosmicdancer

  • Member
  • Posts: 150
It's a therapeutic vaccine, not just preventative.  In fact, on Theraclone Sciences' website, they say they may be useful for HIV positive people who are resistant to existing drugs.  Here's a description of their therapeutic programs from their website.

HIV:  In collaboration with IAVI, Theraclone has discovered a large panel of broadly neutralizing and highly potent anti-HIV monoclonal antibodies that recognize novel epitopes present in a broad range of viruses in circulation. IAVI is investigating these epitopes to potentially inform and guide vaccine design against HIV. The antibodies may be useful as therapeutic drug candidates to treat HIV infections, such as in patients resistant to existing drugs. Theraclone’s aim is to identify a licensee for the therapeutic use of these monoclonal antibodies.

http://www.theraclone-sciences.com/therapeutic-programs.php
Summer, 2007 - &$#@?
November, 2007 - Tested poz, 300,000 vl, 560 cd4
Feb, 2008 - 57,000 vl, 520 cd4, started Atripla
June, 2008 - undetectable, 612 cd4
January, 2009 - undetectable, 670 cd4
May, 2009 - undetectable, 593 cd4
Sept, 2009 - 83 vl, 763 cd4, 34%
Dec, 2009 - undetectable, 889 cd4, 32%
April, 2010 - undetectable, 860 cd4, 31%
October, 2010 - undetectable, 800 cd4, 38%
April, 2011 - undetectable, t-cell test not done
October, 2011 - undetectable
April, 2012 - undetectable, 850 cd4, 39%
November, 2012 - undetectable, 901 cd4, 41%
April, 2013 - undetectable, 846 cd4, 36%
October, 2013 - undetectable
May, 2014 - undetectable, 784 cd4, 48%

Offline tryingtostay

  • Member
  • Posts: 197
So how does this vaccine differ from today's hiv meds for people who are HIV+  ??  It's a possible new med for HIV+ individuals who are resistant to today's hiv drug therapy??
Labs:
March 2014: CD4 1730 @ 41%, VL 87 without meds
May 2014: CD4 1309 @ 42%, VL <20 without meds
Sept 2014: CD4 1655 @ 42%, VL xxxx  - waiting for results

Offline geobee

  • Member
  • Posts: 280
I asked about the ABs when I was at Quest screening for the Sangamo trial.  They were conducting a trial -- people got UD with weekly injections.  Some people actually preferred it to taking meds.    I always thought it was salvage therapy but, who knows, maybe it will be more than that.  One good thing is you don't get resistance to the ABs.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.